Evidence map›Paper›PMID 38986442›Full record

ReviewImmunity2024

Antibody modulation of B cell responses-Incorporating positive and negative feedback.

Jason G Cyster, Patrick C Wilson

Abstract readReview
In one paragraph

Review in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. Trial
  2. Trial
  3. A stealth delivery platform for B cell-based immunity.Molecular therapy. Nucleic acids · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Extrafollicular and other non-germinal center B cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jason G CysterHoward Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: jason.cyster@ucsf.edu.
Patrick C WilsonDrukier Institute for Children's Health, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA. Electronic address: pcw4001@med.cornell.edu.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
B LYMPHOCYTE MIGRATION AND HOMEOSTASISR01AI040098 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason G Cyster · 1997 to 2026
$7.0M
Beta Lymphocyte Migration and HomeostasisR37AI040098 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 2002 to 2011
$3.2M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS R01 AI040098NIAID NIH HHS R37 AI040098
6 · The paper itself

Abstract

Antibodies are powerful modulators of ongoing and future B cell responses. While the concept of antibody feedback has been appreciated for over a century, the topic has seen a surge in interest due to the evidence that the broadening of antibody responses to SARS-CoV-2 after a third mRNA vaccination is a consequence of antibody feedback. Moreover, the discovery that slow antigen delivery can lead to more robust humoral immunity has put a spotlight on the capacity for early antibodies to augment B cell responses. Here, we review the mechanisms whereby antibody feedback shapes B cell responses, integrating findings in humans and in mouse models. We consider the major influence of epitope masking and the diverse actions of complement and Fc receptors and provide a framework for conceptualizing the ways antigen-specific antibodies may influence B cell responses to any form of antigen, in conditions as diverse as infectious disease, autoimmunity, and cancer.

Indexed as

B-LymphocytesCOVID-19SARS-CoV-2AnimalsAntibodies, ViralAntibody FormationFeedback, PhysiologicalHumansImmunity, HumoralMiceReceptors, FcAntibodies, ViralReceptors, Fc

Identifiers

PMID38986442
PMCPMC11257158

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.